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Abstract
Genome-wide association studies (GWAS) of psychiatric phenotypes have tended to focus on categorical diagnoses, but to
understand the biology of mental illness it may be more useful to study traits which cut across traditional boundaries. Here,
we report the results of a GWAS of mood instability as a trait in a large population cohort (UK Biobank, n= 363,705). We
also assess the clinical and biological relevance of the findings, including whether genetic associations show enrichment for
nervous system pathways. Forty six unique loci associated with mood instability were identified with a SNP heritability
estimate of 9%. Linkage Disequilibrium Score Regression (LDSR) analyses identified genetic correlations with Major
Depressive Disorder (MDD), Bipolar Disorder (BD), Schizophrenia, anxiety, and Post Traumatic Stress Disorder (PTSD).
Gene-level and gene set analyses identified 244 significant genes and 6 enriched gene sets. Tissue expression analysis of the
SNP-level data found enrichment in multiple brain regions, and eQTL analyses highlighted an inversion on chromosome 17
plus two brain-specific eQTLs. In addition, we used a Phenotype Linkage Network (PLN) analysis and community analysis
to assess for enrichment of nervous system gene sets using mouse orthologue databases. The PLN analysis found enrichment
in nervous system PLNs for a community containing serotonin and melatonin receptors. In summary, this work has
identified novel loci, tissues and gene sets contributing to mood instability. These findings may be relevant for the
identification of novel trans-diagnostic drug targets and could help to inform future stratified medicine innovations in mental
health.
Introduction
Mood instability is a subjective emotional state defined as
rapid oscillations of intense affect, with difficulty regulating
these oscillations and their behavioural consequences [1].
As a psychopathological phenotype, mood instability may
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be useful for psychiatric research within a Research Domain
Classification (RDoC) framework [2] because it is a
symptom that occurs in several psychiatric disorders, par-
ticularly major depressive disorder (MDD) and bipolar
disorder (BD). It is also present within general population
samples, and is known to be associated with a range of
adverse health outcomes [3].
We recently identified four loci associated with mood
instability within a subsample of the UK Biobank cohort
(n= 113,968) and found genetic correlation with both
MDD and schizophrenia [4]. Here, we report a significantly
larger genome-wide association study (GWAS) of mood
instability in the European ancestry subset of UK Biobank
dataset (n= 363,705), using a BOLT-LMM approach to
maximise statistical power. We also revisit the assessment
of genetic correlations with psychiatric disorders, including
the use of more recent GWAS outputs for MDD, schizo-
phrenia and BD. Furthermore, we contextualise our findings
in terms of affected tissues, eQTL analysis and Phenotype
Linkage Network (PLN) analysis. PLN is a new metho-
dology that harnesses the fact that variation in many com-
plex traits results from perturbations of multiple molecular
components within a smaller number of cellular pathways.
These pathways can then be identified using gene network
approaches.
Methods
UK Biobank sample
UK Biobank is a large cohort of over 500,000 United
Kingdom residents, aged between 39 and 69 years [5]. UK
Biobank was created to study the genetic, environmental
and lifestyle factors that cause or prevent a range of mor-
bidities in middle and older age. Baseline assessments
occurred over a 4-year period, from 2006 to 2010, across 22
UK centres. These assessments covered a wide range of
social, cognitive, lifestyle and physical health measures.
Informed consent was obtained from all participants, and
this study was conducted under generic approval from the
NHS National Research Ethics Service (approval letter
dated 13 May 2016, Ref. 16/NW/0274) and under UK
Biobank approvals for application #6553 ‘Genome-wide
association studies of mental health’ (PI Daniel Smith).
Genotyping, imputation and quality control
In March 2018, UK Biobank released genetic data for
487,409 individuals, genotyped using the Affymetrix UK
BiLEVE Axiom or the Affymetrix UK Biobank Axiom
arrays (Santa Clara, CA, USA) which contain over 95%
common SNP content [6]. Pre-imputation quality control,
imputation and post-imputation cleaning were conducted
centrally by UK Biobank (described in the UK Biobank
release documentation).
Phenotyping
UK Biobank participants were asked as part of their base-
line assessment: “Does your mood often go up and down?”
Those who responded ‘yes’ to this question were defined as
mood instability cases and those who responded ‘no’ were
defined as controls. To minimise any impact of psychiatric
disorders on observed genetic associations with mood
instability, individuals reporting depression, bipolar dis-
order, schizophrenia, ‘nervous breakdown’, self-harm or
suicide attempt (all from UK Biobank data field 20002), and
those who reported taking psychotropic medications (data
field 20003) were excluded from the analysis. Participants
were also excluded if: their self-reported sex did not match
their genetically determined sex; UK Biobank had deter-
mined them to have sex chromosome aneuploidy; they were
considered by UK Biobank to be heterozygous outliers;
they were missing over 10% of their genetic data; or they
were not in the subset classified as British participants of
European ancestry.
Genetic association and heritability
Genetic association analysis was performed using BOLT-
LMM [7, 8]. This approach makes use of a genetic rela-
tionship matrix (GRM) to control as robustly as possible for
population structure without the need to adjust the model
for principal components (PCs), while maximising power
by avoiding the need to exclude related individuals. In
addition, BOLT-LMM builds an infinitesimal model
including all directly genotyped SNPs simultaneously,
thereby further increasing power compared with logistic
regression approaches that test each SNP in turn. This
‘genotyped SNPs only’ model has the imputed SNPs tested
against it allowing for the imputation score cut-off criterion
to be substantially reduced and increases the number of
SNPs available to test for association with the outcome.
BOLT-LMM treats binary variables as a linear trait but is
able to handle binary outcomes well when the sample size is
large and when the number of cases and controls are evenly
balanced, as is the case here.
Models were adjusted for age, sex and genotyping array.
SNPs were filtered to remove those with MAF < 0.01,
Hardy-Weinberg Equilibrium p < 1 × 10−6, or imputation
quality score <0.3. BOLT-LMM was also used to provide a
heritability estimate and λGC estimate. A secondary analysis
was also performed on a subsample of the cohort which
excluded those used in the previous GWAS and anyone
who was related to another participant.
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Regional plots were made via LocusZoom v1.4 [9]
as FUMA lacks SNPs from the HRC reference panel
which were also imputed in the UK Biobank genetic
data release. We defined a locus as the region of
containing a lead SNP and all other SNPs (r2 > 0.1)
within a 5 MB radius of the lead SNP. The LD was
calculated using 10,000 unrelated Biobank partici-
pants who had passed the same genetic QC as those
used for the GWAS.
The summary statistics were processed by FUMA [10]
(See URLs) for visualisation, MAGMA Gene Analysis,
Gene-set Analysis and Tissue Expression Analysis [11].
The Gene-level Analysis operates by grouping p values for
individual SNPs into a gene test statistic using the mean χ2
statistic for the gene whilst accounting for LD via the use of
a European ancestry reference panel. The Gene-set Analysis
groups genes according to MsigDB v6.1 [12], a collection
of both curated gene sets and GO terms, and tests each set in
turn against all the other sets. The Tissue Expression Ana-
lysis performs a one-sided test based on the correlation
between tissue-specific gene expression profiles and trait-
gene associations.
Genetic correlations
Linkage Disequilibrium Score Regression (LDSR) [13] was
used to calculate genetic correlations with psychiatric dis-
orders. The intercept was left unconstrained to allow for
sample overlap. For the MDD [14], BD [15], schizophrenia
[15] and PTSD [16] phenotypes, we used the most up-to-
date GWAS summary statistics provided by the Psychiatric
Genomics Consortium. Anxiety disorder summary statistics
came from the Anxiety NeuroGenetics STudy (ANGST)
Consortium [17].
Tissue-specific expression and eQTL analysis
The lead SNP for each locus (unless otherwise noted)
was assessed for cis effects on gene expression (eQTLs)
in publicly available human dorsolateral prefrontal cor-
tex RNASeq datasets using the Lieber Institute for Brain
Development (LIBD) eQTL browser (See URLs). Each
locus was initially examined in the LIBD BrainSeq
dataset (n= 738; See URLs); SNPs showing significant
eQTLs were then assessed for replication in the Common
Mind Consortium (CMC) dataset (n= 547; See URLs).
Only eQTLs that reached a False Discovery Rate (FDR)
corrected threshold of q ≤ 0.05 in both the LIBD and
CMC datasets, and showed the same direction of effect in
both, are reported. Tissue-specific expression patterns
were assessed for implicated genes using the GTEx
portal [18]. All q values quoted in the text are FDR
corrected.
Genetic principal component generation
Genetic principal components were created using Plink 2 [19]
using pca approx (with default settings) within the region
between base positions 40,850,001 and 41,850,000 on chro-
mosome 17 for the analysis of the inversion polymorphism.
Pathway analysis
PLN analysis builds on the fact that variation in complex
traits results from perturbations of multiple molecular com-
ponents within a smaller number of cellular pathways that can
be identified using gene network approaches. No single
dataset or data type can provide a complete picture of the
functional association between genes but a recent method
combines information from multiple data types by weighing
functional similarities between genes according to their like-
lihood of influencing the same mammalian phenotype(s).
This approach has a greater specificity and sensitivity than
analyses using a single data type and other comparable
integrative methods [20]. The PLN approach exploits phe-
notypic information from over seven thousand genes whose
function has been experimentally perturbed in the mouse and
evaluates the ability of different data types such as protein–
protein interactions (PPI), co-expression (RNA or protein)
and semantic similarity score based on literature or Gene
Ontology (GO) annotations or pathway annotations (KEGG),
to predict whether knockout of the orthologues of a given pair
of human genes will yield similar phenotypes. By weighting
those data types accordingly, they are integrated to generate a
single combined measure of functional similarity between
gene pairs. The resulting network of pairwise gene functional
similarities is termed a phenotypic-linkage network (PLN)
[20]. To increase the sensitivity and specificity to detect
functional associations relevant for a specific disease/trait, it is
possible to select only those mouse phenotypes that are
relevant for a specific disorder in the data type weighting
evaluation step [21]. Following this approach, we conducted
a further analysis in which we re-weighted our generic PLN
to be more sensitive to functional genomics data most
informative to mood instability by considering only pheno-
types within the over-arching mouse phenotype ontology
(MPO) category Nervous System (MP:0003631). The PLN
and nervous-PLN (NS-PLN) were built using the same 16
functional genomics datasets described by Honti et al. [20],
with 64,640,972 and 49,656,123 weighted links, respectively.
Following the approach described by Sandor et al. [21],
we identified ‘communities’ of densely interconnected
groups of genes (including at least 20 genes) within each
PLN and tested whether any communities were enriched in
genes harboured by GWA/subGWA intervals. This test
examines how many of these intervals harboured at least
one gene belonging to a given Community as compared to
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randomly shifted intervals equal in gene number. This
approach makes no prior hypothesis about the number or
nature of genes within each GWA interval.
Definition of GWA and subGWA intervals
The GWA and subGWA intervals were defined by con-
sidering SNPs attaining an association p-value of 5 × 10−8
and 1 × 10−6. This identified 6375 (GWA) and 9358 (sub-
GWA) SNPs respectively. We then identified the haplotypic
block containing each of these of these SNPs using geno-
types in the 1000 Genome Project and the python pipeline
developed by Brent Pedersen (See URLs). We defined
GWA/sub GWA intervals by identifying the most distant
block on a chromosome within a region of 500 kb of the
lead SNP. We then added an additional 300 kb on either
side of the interval to include genes that may be regulated
by regulatory variants with effects captured by the lead
SNPs. For subGWA regions, we excluded those subGWA
intervals harbouring genes present in GWA intervals.
Results
Demographics
In this GWAS sample of 363,705 individuals without a
history of psychiatric disorder, 43.2% reported mood
instability (n= 157,039) and the rest did not (n= 206,666).
There was a higher proportion of females amongst the mood
instability cases than in controls (55.4% vs. 51.2%,
respectively), and the mean age of cases was lower than for
controls (55.8 years vs. 57.7 years).
GWAS findings
We detected 46 loci across the genome with p < 5 × 10−8
(Fig. 1 and Table S1) and an estimated SNP heritability (h2)
of 0.09 (SE= 0.02). The heritability estimate has increased
from the previous GWAS by ~2% (Previous h2= 0.07, SE
= 0.007). We attribute the increase in SE to the differing
methodologies. The distribution of test statistics was con-
sistent with a polygenic contribution to risk (λGC=1.21;
λ1000= 1.001; LDSR intercept= 1.041; SE= 0.006). In
addition, to help validate the four loci identified in the
previous mood instability GWAS, we tested the top SNP
from each locus in a sub-sample that excluded individuals
in the previous smaller GWAS and those individuals related
to another Biobank participant (n= 169,857). All four
SNPs were associated with mood instability after Bonfer-
roni correction (α < 0.0125, Table S2). We also note that the
directions of effect were the same as for the previous
GWAS findings.
Gene-level and gene set analysis
A total of 244 significant genes were detected by MAGMA
(Supplementary Table S3) and FUMA gene analysis. The
Gene Set Analysis returned 6 enriched gene sets that met
the threshold for significance after Bonferroni correction
(Supplementary Table S4). Of these, 4 sets were related to
brain development and differentiation of neurons, glial cells
and astrocytes or neurogenesis. Other enriched sets included
the Nikolsky breast cancer 16q24 amplicon genes and the
prepulse inhibition gene sets.
Tissue expression analysis
MAGMA tissue expression analysis identified 11 tissue
categories, all of which were in the brain (Fig. S1). Indeed, all
sampled brain areas except substantia nigra showed enrich-
ment (i.e., frontal and anterior cingulate cortex, basal ganglia,
hippocampus, amygdala, hypothalamus and cerebellum).
Genetic correlations
Genetic correlations were calculated between mood instability
and five psychiatric phenotypes of interest (Table 1). All
genetic correlations remained significant after FDR correction
(q < 0.05). The largest correlations were with MDD (rg= 0.74,
q= 8.50 × 10−157) and anxiety (rg= 0.64, q= 8.08 × 10−6).
PTSD had a moderate correlation with mood instability (rg=
0.32, q= 1.23 × 10−2) and both schizophrenia and bipolar
disorder had weak but significant correlations (schizophrenia
rg= 0.14, q= 1.60 × 10−5, BD rg= 0.09, q= 0.0012).
eQTL analysis
Nine of the GWAS loci showed significant eQTLs, many
potentially with specific isoforms (summarised in Table S5
and presented in full in Supplementary Table S6). The
strongest evidence of association with expression levels was
for rs669915, an eQTL located within a region of strong
linkage disequilibrium (LD) in chromosome 17q21 resulting
from the existence of a 900 kb inversion polymorphism that is
common in European populations [22]. The extended region
of LD across this portion of the chromosome makes it chal-
lenging to identify causal SNPs or the genes they regulate.
The rs669915 eQTL was most strongly associated with
expression of LRRC37A4P (LIBD dataset minimum q=
1.96 × 10−99; CMC dataset q= 3.99 × 10−65), an expressed
pseudogene, but there are many alternative candidates for
genes regulated by this SNP, including MAPT and CRHR1,
for which it was also an eQTL. (Supplementary Table S5).
The chromosome 17q21 inversion polymorphism has
itself been reported to affect the expression of genes in this
region [23]. We therefore investigated whether rs669915
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might ‘tag’ the expression effects mediated by the inversion
polymorphism in our sample. Using the method of de Jong
and colleagues [23], we constructed genetic principal
components (GPCs) from SNPs within the region between
base positions 40,850,001 and 41,850,000 on chromosome
17. A plot of the first two GPCs is shown in Fig. S2 and
reveals three distinct clusters of individuals, each repre-
senting one of the three inversion polymorphism genotypes,
H1/H1 (right-most cluster; n= 162,113), H1/H2 (middle
cluster; n= 158,506) and H2/H2 (left-most cluster; n=
38,597). The H1 inversion allele had a population frequency
of 0.32, far higher than the frequency reported by de Jong.
In linear regression analyses, there was no association
between mood instability phenotype and inversion genotype
using a model of additive allelic effects (no. of H2 alleles)
and adjusting for age, sex and genotyping array (p= 0.835).
Nervous system PLN analyses (NS-PLN)
Amongst both GWA and subGWA gene sets, we found a
disproportionate aggregation of genes within only one
community, Community 26 within the NS-PLN (21 GWAS
loci including at least one gene, q= 0.011; 25 “subGWAS
“loci including at least one, q= 0.018) (Fig. 2a). Examining
the entire NS-PLN Community 26 gene, we found that it was
significantly enriched in genes, whose unique 1:1 orthologues
in the mouse when disrupted induce abnormities in synaptic
transmission (Mouse Phenotype Ontology term MP:0003635;
q= 2.77e−118, 75 genes expected vs. 259 gene observed).
However, we did not find evidence that the unique mouse
orthologues of mood instability GWA and subGWA genes
that belonged to Community 26 were enriched for any par-
ticular mouse phenotype. Nonetheless, we found that the 37
and 35 GWA and subGWA genes present in the Community
26 were highly functionally connected with other Community
26 genes annotated with abnormal synaptic transmission
phenotype term (Fig. 2b).
Discussion
Main findings
These analyses represent the largest genetic study of mood
instability to date. Forty six associated loci were identified,
with a heritability estimate of 9%. Our findings confirm the
four loci identified in our initial GWAS on the UK Biobank
interim data release [4] and are further validated by tissue
expression analyses (enrichment for 11 brain regions) and
pathway analyses (6 enrichment pathways, 4 of which relate
to the development and differentiation of neurons). The
large number of individuals in this study also provided
substantial power to detect genetic correlations with psy-
chiatric traits via LDSR. All five psychiatric traits assessed
had a significant genetic correlation with mood instability.
Some of these correlations were strong (particularly for
Table 1 Genetic correlations of mood instability with psychiatric
phenotypes
Trait rg S.E. Z p q
MDD 0.74 0.03 26.7 1.70 × 10−157 8.50 × 10−157
Anxiety 0.64 0.14 4.7 3.23 × 10−6 8.08 × 10−6
PTSD 0.32 0.13 2.5 1.12 × 10−2 1.23 × 10−2
Schizophrenia 0.14 0.03 4.4 9.57 × 10−6 1.60 × 10−5
Bipolar disorder 0.09 0.037 2.5 1.23 × 10−2 1.23 × 10−2
rg= genetic correlation with mood instability, S.E.= standard error of
the genetic correlation, Z= the test statistic, p= the p value, q the
False discovery rate corrected p value
MDD major depressive disorder, PTSD post-traumatic stress disorder
Fig. 1 Manhattan and QQ plot of mood instability GWAS
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MDD and anxiety) but others were weaker than expected.
For example, the genetic correlation between mood
instability and BD was only 9%, perhaps suggesting that the
mood instability phenotype in this study differs from the
affective instability that is a core feature of BD.
Biology of mood instability
Loci associated with mood instability included genes that
are involved across a variety of biochemical pathways, as
well as brain development and function. For example,
several gene products localised to the synapse. PLCL1 and
PLCL2 are involved in GABA signalling [24] and melato-
nin signalling, respectively, and RAPSN assists in anchoring
nicotinic acetylcholine receptors at synaptic sites [25].
PLCL1 has already been identified in a GWAS of schizo-
phrenia [26] and PLCL2 has been shown to be upregulated
in bipolar disorder [27]. In addition, we identified CALB2
which has many biological functions, including a role in
modulating neuronal excitability [28]. Both DCC (identified
in the previous mood instability GWAS) and BSN facilitate
the release of neurotransmitters within the active zone of
some axons [29]. BSN has also been shown to be associated
with schizoaffective disorder via GABA signalling [30].
FARP1 promotes dendritic growth [31] and, although it has
so far not been directly linked to psychiatric disorders, it has
been shown to regulate dendritic complexity [32] (reduced
dendritic complexity is a recognised feature of schizo-
phrenia [33]).
We identified several developmental genes, including
NEGR1 [34], RARB [35] and EPHB1 [36], and transcription
factors such as HIVEP2 (loss of function of which causes
intellectual disability [37]) and TCF4 (previously associated
with schizophrenia [38]). NEGR1 was identified by 23andMe
within their GWAS of MDD [39] and increased levels of
NEGR1 protein in spinal fluid have been identified in both
MDD and BD [40]. RARB is involved in retinoic acid
synthesis pathways that have been associated depressive
symptoms in mice [41] and has also been found to have
increased expression in patients with schizophrenia [42]. The
methylation state of the EPHB1 gene has been linked to
MDD [43] and SNP-based analyses have identified associa-
tion between EPHB1′s and symptoms of schizophrenia [44].
We also found association with several genes involved in
mitochondrial energy production, such as NDUFAF3,
NDUFS3, PTPMT1, KBTBD4 and MTCH2, suggesting that
part of the physiology of mood instability may relate to
energy dysregulation.
Fig. 2 Different Mood associated genetic risk variants converge in a
nervous specific gene network. a Enrichments of gene functional
communities from a generic PLN and from a Nervous-System (NS)
PLN within Mood-GWA and subGWA loci (see Methods). The
Community ID is given first in the descriptor followed by the number
of genes within that community. Only communities formed from over
20 genes are shown. b Gene subnetwork of Community 26 from NS-
PLN showing functional associations between genes residing in
Mood-associated GWA (red squares) and subGWA (orange squares)
intervals and genes whose unique mouse orthologues are annotated
with abnormal synaptic transmission phenotype (cyan squares). To
increase clarity, only genes with abnormal synaptic transmission
phenotype annotation with at least three functional links to genes
residing in GWA and subGWA regions are shown. The colour of the
link connecting two genes indicates the strongest information source
supporting the functional association
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In addition to protein coding genes, several loci were
identified in regions containing non-coding protein
sequences such as AC019330.1, AC133680.1, RP11-6N13.1
and RP11-436d23.1. In addition, eQTL analyses identified
three more possible non-coding genes (RP11-481A20.10,
RP11-481A20.11 and FAM85B) suggesting a possible RNA
interference or post-transcriptional regulation basis to mood
instability.
Furthermore, the eQTL analyses highlighted the 17q21
inversion. Our principal component analysis of this region
did not detect a significant association leading us to conclude
that it is the SNPs in the region (not the inversion itself)
driving the association. It is possible that lead SNPs may tag,
enhancer RNA or eRNA which we were unable to detect
here (LIBD data was generated using poly-A RNA and so
targets messenger RNA). However, our findings are con-
sistent with a recent report implicating dopamine neuron-
enriched enhancer activity in this region in several dopamine-
related psychiatric and neurological conditions [45].
Genes within regions associated with mood instability
were functionally associated with synaptic transmission, a
key pathway for psychiatric disorders, albeit this functional
association was only detectable after focussing our gene
network towards data types most informative for mamma-
lian nervous system phenotypes. Among the genes lying
within associated loci that contribute to this functional
association are several interesting candidate genes. HTR4 is
a member of the family of serotonin receptors and impli-
cated in depression and its treatment [46]. MCHR1, melanin
concentrating hormone receptor 1, is a G protein-coupled
which binds melanin-concentrating hormone. MCHR1 can
inhibit cAMP accumulation and stimulate intracellular cal-
cium flux, and may be involved in the neuronal regulation
of food consumption [47] and the locus showed association
with schizophrenia in a Danish sample [48].
Strengths and limitations
As noted above, this is the largest GWAS of a mood
instability phenotype to date and has successfully identified
new loci, eQTLs, tissues, genetic correlations and gene
network enrichments. However, there are several limita-
tions, most notably the use of a single question to define
mood instability, and the lack of objective verification of
this phenotype. There are more detailed suggested mea-
surement scales for mood instability, such as that developed
by Chaturvedi and colleagues [49]. In the future, the use of
these more comprehensive assessments in large samples
may provide some clarification of our findings, for example
the lack of strong genetic correlation between mood
instability and BD. Nevertheless, the single question
approach to mood instability has been widely used, and
shown to identify robust associations with a range of health
outcomes and disorders [1, 3]. Similarly, exclusions for
psychiatric disorder were based on self-report.
We validated the top hits of the previous GWAS, how-
ever the cohort used was not truly independent (it was also
part of the UK Biobank cohort). It would be of interest to
replicate the 46 loci identified here, in sufficiently large
independent replication cohorts, when they become avail-
able in the future. As well as replication of the loci, further
analysis of sex specific differences would be of interest
because mood instability was more common in females than
males. Although this difference was relatively small, our
reported analyses were adjusted for sex and these differ-
ences are similar to those reported elsewhere [50].
It is also important to note that direct links between genetic
risk loci and network constituents in the PLN analysis will
have to await the release of more completely annotated gene
databases. The incompleteness of phenotypic annotations is
likely to explain why the genes identified in the PLN analysis
do not have corresponding organismal or physiological phe-
notypes, but the fact that there were strong functional asso-
ciations between the genes in the network we detected and
mouse orthologues that have the synaptic transmission phe-
notype annotation suggests that the mood instability genes
will also reveal this phenotype when more completely
annotated databases become available.
Finally, we note the large difference in frequencies of the
inversion polymorphism on chromosome 17 from that
reported by De Jong [23]. This difference could be due to
the populations sampled to estimate the frequency or over
representation in those who joined UK Biobank. It is
however important to note that the inversion itself would be
likely to contribute only a small proportion of the mood
instability phenotype, such that even larger sample sizes
than were used here would be needed to detect a correlation
where one exists.
Conclusion
In summary, with a tripling in sample size from the previous
GWAS, we identified substantially more associations with
mood instability in the UK Biobank cohort [4]. Future
analyses of the precise roles that these associations play in
the clinical expression of mood instability will be relevant
for the wide range of psychiatric phenotypes in which mood
instability occurs. We have also been able to more con-
fidently place these GWAS findings within relevant
biological contexts and some of the loci and pathways
identified may represent candidates for future novel drug
development.
Our findings are also of interest in the context of preci-
sion medicine innovations for mental health. It is possible
that polygenic risk scores derived from this work could be
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applied to clinical populations to conduct pharmacoge-
nomics studies and to inform patient stratification approa-
ches. Overall, we hope that our findings will stimulate
further research on the biology and treatment of
mood instability across a range of mood and psychotic
disorders.
URLs
FUMA–http://fuma.ctglab.nl/
Python pipeline developed by Brent Pedersen–https://gist.
github.com/brentp/5050522
LIBD website–http://eqtl.brainseq.org/
LIBD eQTL Browser phase 1–http://eqtl.brainseq.org/pha
se1/eqtl/
CommonMind Consortium public–private partnership–
http://commonmind.org/WP
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